Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
// Pradip De 1,2 , Jennifer Carlson 1 , Brian Leyland-Jones 1,2 and Nandini Dey 1,2 1 Department of Molecular & Experimental Medicine, Avera Research Institute, Sioux Falls, SD 2 Department of Internal Medicine, SSOM, University of South Dakota, Sioux Falls, SD Correspondence: Nandini Dey, email: // Keywords : CIP2A, PP2A, c-MYC, Cancers, Prognosis, Biomarkers Received : April 16, 2014 Accepted : June 20, 2014 Published : June 22, 2014 Abstract Oncoprotein CIP2A a Cancerous Inhibitor of PP2A forms an “oncogenic nexus” by virtue of its control on PP2A and MYC stabilization in cancer cells. The expression and prognostic function of CIP2A in different solid tumors including colorectal carcinoma, head & neck cancers, gastric cancers, lung carcinoma, cholangiocarcinoma, esophageal cancers, pancreatic carcinoma, brain cancers, breast carcinoma, bladder cancers, ovarian carcinoma, renal cell carcinomas, tongue cancers, cervical carcinoma, prostate cancers, and oral carcinoma as well as a number of hematological malignancies are just beginning to emerge. Herein, we reviewed the recent progress in our understanding of (1) how an “oncogenic nexus” of CIP2A participates in the tumorigenic transformation of cells and (2) how we can prospect/view the clinical relevance of CIP2A in the context of cancer therapy. The review will try to understand the role of CIP2A (a) as a biomarker in cancers and evaluate the prognostic value of CIP2A in different cancers (b) as a therapeutic target in cancers and (c) in drug response and developing chemo-resistance in cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 1×
“In line with (a) CIP2A’s reported ability to protect c-MYC against proteasome-mediated degradation [27] and (b) mTORC1’s capability to integrate information regarding the availability of nutrients and energy to coordinate protein synthesis and autophagy [28-31], this evidence that CIP2A is functionally connected to th…”
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 5×
“CIP2A controls oncogenic cellular signals by suppressing tumor suppressor PP2A [2, 12, 14].”
InfluentialProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · cited 4×
“CIP2A is a rare inhibitor of tumor suppressor PP2A, protein phosphatase which dephosphorylates several well-known oncogenes including MYC, beta-catenin, AKT and BCL2 [3, 4].”
InfluentialPP2A: Unveiling a Reluctant Tumor Suppressor
Mumby, M. (2007) · Cell · doi:10.1016/j.cell.2007.06.034 · Cited by 295
Arnold, H. K., & Sears, R. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2832-2844.2006 · Cited by 251 · cited 2×
“PP2A has been identified as a protein involved in regulating c-MYC expression [11].”
Hoo, L. S., Zhang, J. Y., & Chan, E. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205625 · Cited by 201 · cited 1×
“CIP2A is rarely present (low levels) in non-transformed/non-malignant cells while in a typically transformed cell, CIP2A is present in abundance [37].”
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185 · cited 2×
“[48].”
Khanna, A., Pimanda, J. E., & Westermarck, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1994 · Cited by 154
Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011) · Blood · doi:10.1182/blood-2010-08-304477 · Cited by 138
Cited by
CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease
Shentu, Y.-P., Huo, Y., Feng, X.-L., Gilbert, J., Zhang, Q., Liuyang, Z.-Y., Wang, X.-L., Wang, G., Zhou, H., Wang, X.-C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.009 · Cited by 90
“Actually, drugs have been identified aiming to inhibit CIP2A in cancer therapy (De et al., 2014).”
BackgroundAllen-Petersen, B. L., Risom, T., Feng, Z., Wang, Z., Jenny, Z. P., Thoma, M. C., Pelz, K. R., Morton, J. P., Sansom, O. J., Lopez, C. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0717 · Cited by 85
The role of CIP2A in cancer: A review and update
Soofiyani, S. R., Hejazi, M. S., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.146 · Cited by 72
Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers
Khanna, A., & Pimanda, J. E. (2016) · International Journal of Cancer · doi:10.1002/ijc.29431 · Cited by 57
Metadata
- Authors
- De, P., Carlson, J., Leyland-Jones, B., & Dey, N.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-06-22
- Volume
- 5
- Issue
- 13
- Pages
- 4581-4602
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1861563384
- Cited by
- 73
- References
- 20
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands. https://app.cochat.ai/papers/10.18632/oncotarget.2127
- The paper
- De, P., Carlson, J., Leyland-Jones, B., & Dey, N. (2014). Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands. Oncotarget. https://doi.org/10.18632/oncotarget.2127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.